Trial Profile
A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Defactinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Nov 2014 Results published in the Drugs of the Future.
- 28 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.